— Know what they know.
Not Investment Advice

CMPS

COMPASS Pathways plc
1W: -4.4% 1M: -29.7% 3M: -13.9% YTD: -14.2% 1Y: +80.7% 3Y: -33.7% 5Y: -85.9%
$5.62
+0.40 (+7.66%)
After Hours: $5.78 (+0.16, +2.76%)
NASDAQ · Healthcare · Medical - Care Facilities · $540.0M · Alpha Radar Sell · Power 36
Smart Money Score
Watch 25
Insider+$0.3M
Congress
ETF Holdings
Key Statistics
Market Cap$540.0M
52W Range2.25-8.9
Volume2,034,363
Avg Volume2,838,867
Beta1.91
Dividend
Analyst Ratings
12 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOKabir Kumar Nath
Employees166
SectorHealthcare
IndustryMedical - Care Facilities
IPO Date2020-09-18
33 Broadwick Street
London W1F 0DQ
GB
44 64 6905 3974
About COMPASS Pathways plc

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Recent Insider Trades

NameTypeSharesPriceDate
Nath Kabir F-InKind 13,131 $6.89 2026-03-11
Loxam Teri F-InKind 1,781 $6.89 2026-03-11
Loxam Teri F-InKind 4,467 $7.02 2026-03-02
Nath Kabir F-InKind 16,181 $6.61 2026-02-02
JONAS JEFFREY M A-Award 52,000 $6.33 2025-10-29

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms